UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis

Internal medicine journal, 2014-08, Vol.44 (8), p.764-770

2014

Volltextzugriff (PDF)

The development and validation of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease

British journal of dermatology (1951), 2013-11, Vol.169 (5), p.1000-1006

2013

Volltextzugriff (PDF)

Veno-arterial extracorporeal membrane oxygenation for severe cardiogenic shock secondary to phaeochromocytoma crisis

Anaesthesia and intensive care, 2017-09, Vol.45 (5), p.635-637

2017

Volltextzugriff (PDF)

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

Annals of oncology, 2012-08, Vol.23 (8), p.1968-1973

2012

Volltextzugriff (PDF)

1326PExternal validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the surveillance, epidemiology and end results (SEER) program

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the surveillance, epidemiology and end results (SEER) program

Annals of oncology, 2019-10, Vol.30, p.v540

2019

Volltextzugriff (PDF)

1326P - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the surveillance, epidemiology and end results (SEER) program

Annals of oncology, 2019-10, Vol.30, p.v540-v540

2019

Volltextzugriff (PDF)

1232 POSTER Creatinine Clearance (CrCI) as a Predictive Marker for the Risk of Toxicity From Molecularly Targeted Agents (MTA) in Phase I Trials

European journal of cancer (1990), 2011, Vol.47, p.S154-S154

2011

Volltextzugriff (PDF)

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

Oncology, 2012-08, Vol.83 (4), p.177-182

2012

Volltextzugriff (PDF)

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

Annals of oncology, 2012-08, Vol.23 (8), p.1968

2012

Volltextzugriff (PDF)

Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

Cancer, 2022-04, Vol.128 (8), p.1574-1583

2022

Volltextzugriff (PDF)

Survey of medical oncologists and trainee practice on venous thromboembolism prophylaxis and treatment in solid cancers

Internal medicine journal, 2023-01, Vol.53 (1), p.131-135

2023

Volltextzugriff (PDF)

External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program

Asia-Pacific journal of clinical oncology, 2022-10, Vol.18 (5), p.e280-e288

2022

Volltextzugriff (PDF)

Let's talk about cytotoxic chemotherapy dosing: unravelling adjustments and off‐protocol prescribing

Medical journal of Australia, 2019-02, Vol.210 (2), p.65-66

2019

Volltextzugriff (PDF)

Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer

British journal of cancer, 2024-02, Vol.130 (3), p.425-433

2024

Volltextzugriff (PDF)

Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis

Cancer, 2021-07, Vol.127 (14), p.2432-2441

2021

Volltextzugriff (PDF)

Response of a tertiary dermatology department to COVID‐19

Australasian journal of dermatology, 2020-11, Vol.61 (4), p.e468-e469

2020

Volltextzugriff (PDF)

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

European journal of cancer (1990), 2021-09, Vol.154, p.190-200

2021

Volltextzugriff (PDF)

Does chemotherapy improve survival in muscle-invasive bladder cancer (MIBC)? A systematic review and meta-analysis (MA) of randomized controlled trials (RCT)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.4544-4544

2013

Volltextzugriff (PDF)

Clinical utilities and end-user experience of pharmacogenomics: 39 mo of clinical implementation experience in an Australian hospital setting

World journal of medical genetics, 2023-12, Vol.11 (4), p.39-50

2023

Volltextzugriff (PDF)

Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.6014-6014

2020

Volltextzugriff (PDF)

The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy

Acta oncologica, 2020-01, Vol.59 (1), p.20-27

2020

Volltextzugriff (PDF)

‘A most malignant malady’: a rare case of laryngeal tuberculosis in epidermal growth factor receptor mutant lung adenocarcinoma

Internal medicine journal, 2017-10, Vol.47 (10), p.1215-1216

2017

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(26)
Berichte
(1)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis

The development and validation of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease

Veno-arterial extracorporeal membrane oxygenation for severe cardiogenic shock secondary to phaeochromocytoma crisis

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

1326PExternal validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the surveillance, epidemiology and end results (SEER) program

External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the surveillance, epidemiology and end results (SEER) program

1326P - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the surveillance, epidemiology and end results (SEER) program

1232 POSTER Creatinine Clearance (CrCI) as a Predictive Marker for the Risk of Toxicity From Molecularly Targeted Agents (MTA) in Phase I Trials

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

Survey of medical oncologists and trainee practice on venous thromboembolism prophylaxis and treatment in solid cancers

External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program

Let's talk about cytotoxic chemotherapy dosing: unravelling adjustments and off‐protocol prescribing

Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer

Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis

Response of a tertiary dermatology department to COVID‐19

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

Does chemotherapy improve survival in muscle-invasive bladder cancer (MIBC)? A systematic review and meta-analysis (MA) of randomized controlled trials (RCT)

Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy

Clinical utilities and end-user experience of pharmacogenomics: 39 mo of clinical implementation experience in an Australian hospital setting

Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy

The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy

‘A most malignant malady’: a rare case of laryngeal tuberculosis in epidermal growth factor receptor mutant lung adenocarcinoma

Suchergebnisse filtern